As part of its long-term strategy to expand its capabilities in bioengineering technologies, Givaudan announced yesterday that it will acquire Alderys, a French biotechnology company based in Orsay, France, for the chemical and cosmetic industry sectors, in addition to nutrition.

Maurizio Volpi, President of Givaudan’s Fragrance Division said: “The acquisition of Alderys aligns with our long term strategy for Active Beauty and more specifically, their expertise in biotechnology is fully complementary to our Fragrance and Active Beauty businesses”.

Givaudan hopes to expand its portfolio of natural products and biological sources. “Givaudan hopes to expand its portfolio of natural products and biological sources. “It will be an additional tool to drive our future development and innovationin the active cosmetic ingredients spaceand beyond, in addition to supporting customers in the development of sustainable products with performance.”

Dominique Thomas, CEO of Alderys added: “We strongly believe this is a great opportunity to expand our scientific expertise to the service of the beauty, fragrance and flavour industry, whilst we will continue to serve our other historical and future partners.”

“Alderys has a strong track record in designing innovative biological pathways to produce environmentally-friendly raw materials, which is essential to the way we develop our cosmetic ingredients,” said Laurent Bourdeau, Head of Givaudan’s Active Beauty Business.

Givaudan plans to fund the transaction from existing resources. The planned acquisition is subject to formal approvals from the relevant regulatory authorities and the transaction is expected to close in the second quarter of 2020.

In February this year, the company has acquired of Ungerer & Company, the US based Flavour, Fragrance and Specialty Ingredients company.